Gabelli Funds LLC lowered its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 66.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,000 shares of the medical instruments supplier’s stock after selling 62,200 shares during the period. Gabelli Funds LLC’s holdings in Becton Dickinson and were worth $8,064,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after buying an additional 416,459 shares in the last quarter. Fundsmith LLP boosted its holdings in Becton Dickinson and by 0.9% during the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after buying an additional 35,453 shares in the last quarter. Northern Trust Corp boosted its holdings in Becton Dickinson and by 0.7% during the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after buying an additional 23,645 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Becton Dickinson and by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock worth $721,582,000 after buying an additional 223,215 shares in the last quarter. 84.26% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Charles R. Bodner sold 1,514 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the transaction, the senior vice president now owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the transaction, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. In the last three months, insiders sold 37,249 shares of company stock valued at $9,616,803. Company insiders own 0.12% of the company’s stock.
NYSE:BDX opened at $260.70 on Friday. The firm has a 50 day simple moving average of $252.49 and a 200-day simple moving average of $245.37. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. The firm has a market cap of $70.77 billion, a PE ratio of 23.68, a P/E/G ratio of 1.89 and a beta of 1.13. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. The business had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company’s revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.91 earnings per share. As a group, sell-side analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
A number of analysts recently commented on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies cut their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Raymond James lifted their target price on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $266.55.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.